HeyJaredVictoria Stern
- Indexed articles, last 90 days
- 15
- Latest publication
- Sep 16, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 20, 2026
Latest articles
Pelvic RT Tied to Longer Survival in Cervical Cancer (opens the original)
Read excerpt
Definitive-dose pelvic radiotherapy (RT) combined with chemotherapy was associated with longer overall survival compared with chemotherapy alone in patients with newly diagnosed stage IVB cervical cancer, with 2-year overall survival rates of 50.3% in the RT group vs 31.0% in the chemotherapy-only group after propensity score matching. "These findings suggest that intensified local treatment may benefit selected patients, warranting confirmation in prospective randomised trials," the authors wro
Prostate Cancer Spending Nearly Quadrupled Over 10 Years (opens the original)
Read excerpt
Prostate cancer–related Medicare spending nearly quadrupled from 2012 to 2021, rising from $504 million to $1.9 billion, according to a population-level economic analysis. Systemic therapy, especially second-generation androgen receptor–targeted therapies, accounted for an increasing share of spending. The findings “demonstrate not merely an increase in spending, but a fundamental shift in where healthcare dollars are being allocated,” according to authors of an invited commentary. While “the ob
Bilateral Mastectomy Rises in Young BRCA1/2 Carriers (opens the original)
Read excerpt
Among young women carrying germline BRCA1/2 pathogenic or likely pathogenic variants diagnosed with early-onset breast cancer, bilateral mastectomy rates increased substantially over two decades, rising from 8% in 2000 to 44.4% in 2020, a recent international study found. Women who underwent genetic testing before or at the time of diagnosis were significantly more likely to undergo bilateral mastectomy compared with those tested after diagnosis. "The findings of this cohort study of young BRCA1
Shorter RT Schedule Linked to Worse Glioblastoma Survival (opens the original)
Read excerpt
Ultrahypofractionated radiotherapy for newly diagnosed glioblastoma was associated with shorter survival than standard fractionation, with median overall survival of 13 months vs 21 months. Radiation necrosis or pseudoprogression occurred about five times more often after ultrahypofractionation, although no grade 4-5 toxicities were observed. “Noninferiority of the 6 × 6 Gy chemoradiation regimen could not be demonstrated,” the study authors concluded. “This ultrahypofractionated regimen was ass
TIGIT Combo Fails to Improve Outcomes in Stage III NSCLC (opens the original)
Read excerpt
Consolidation therapy with tiragolumab plus atezolizumab did not improve progression-free survival (PFS) or overall survival compared with durvalumab in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) after platinum-based concurrent chemoradiation. “The phase III SKYSCRAPER-03 study demonstrated that tiragolumab plus atezolizumab did not offer additional benefit over durvalumab alone in patients with locally advanced, unresectable, stage III NSCLC who h
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.